Navigation Links
Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Date:3/11/2008

nt options with curative potential, recurrence is common within the first 12 to 15 months following surgery and five-year survival following resection is less than 50%.

Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs, added, "Since the release of our promising phase 2 data last year, our team has worked tirelessly to design a world-class phase 3 trial for PI-88 in liver cancer. We are very thankful for the support of key opinion leaders and clinicians all over the world, many of whom will now be serving as investigators in PATHWAY. While the study is starting later than we had hoped as a result of some delays opening sites due to a greater-than-expected impact from holidays over the past couple of months, Progen continues to aggressively drive country regulatory and hospital ethics approvals to conduct this phase 3 trial."

The study now has regulatory approval in almost half of the participating countries and more than a dozen sites have been granted approval by ethics committees. Sites are being initiated so as to be able to commence patient recruitment as soon as these necessary approvals have been granted.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In April 2007, data from a randomised phase 2 trial in the post resection liver cancer setting was presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain. PI-88, in this disease setting, has been granted Orphan Drug designation by the European Medicines Evaluation Agency (EMEA) and Fast Track designation by the United States Food and Drug Administration (FDA).
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces ... available in its catalogue: Personal ... Trends and Opportunities to 2018 ... The report provides in depth market analysis, ... accident and health insurance segment, including: - ...
(Date:8/20/2014)... 2014 Reportbuyer.com has added a new market ... https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html This report analyzes ... by the following Product Segments: Implantable/Internal Cardiac Defibrillators, and ... the US, Canada , ... Asia-Pacific , Middle East ...
(Date:8/20/2014)... RANCHO MIRAGE, Calif. , Aug. 20, 2014 ... patient named Fernando Davila has been successfully treated ... eating disease", by Dr, Anibal R. Gauto , Medical ... Care Center, at Eisenhower Medical Center in Rancho ... a new treatment pioneered by Dr. John Crew ...
Breaking Medicine Technology:Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14
... Calif., Sept. 12 Bionovo, Inc.,(Nasdaq: BNVI ... in the journal for,the American Society for Pharmacology ... In Vitro Metabolism of,Liquiritigenin, a Bioactive Compound Isolated ... Liquiritigenin is one of the active compounds ...
... a new study, men with,locally recurrent prostate cancer ... treatment option., A Phase III clinical trial ... is investigating the safety and efficacy of High ... recurrent prostate,cancer following failed external beam radiation therapy ...
Cached Medicine Technology:Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 3High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study 2
(Date:8/21/2014)... mynt welcomes industry leaders Rob and Tiffanie ... growing company. Since its pre-launch in April, mynt has ... continues to gain momentum leading up to its official ... came into network marketing by chance. Tiffanie worked for ... marketing companies. Tiffanie needed help at one particular distributor ...
(Date:8/21/2014)... August 21, 2014 According to ... Application (Biodegradable polymer, Food & Beverage, Personal care ... (Packaging, Agriculture, Automobile, Electronics, Textile) & Geography - ... lactic acid and polylactic acid markets and segments ... each market, based on their sub-segments, in terms ...
(Date:8/21/2014)... Luis Obispo, CA (PRWEB) August 21, 2014 ... edition of Current Pedorthics, a bi-monthly publication of the Pedorthic ... field of pedorthics. , Bunion Bootie ... an alternative solution for bunion sufferers and their pain. It ... worn in nearly any shoe to eliminate the friction and ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 While golfing ... found it hard to stay focused on his game ... mosquitoes. The constant whine, slapping and continual need to ... innovative methods to stay protected from insects while golfing. ... career in the Financial Services/Investment Banking Industry, decided to ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Atlantic Information ... of ACO Business News and The AIS Report on ... the Blue Cross Blue Shield Association or its member ... the latest report in AIS’s Management Insight Series. ... case studies of two insurers — Horizon Healthcare Services, ...
Breaking Medicine News(10 mins):Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 2Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 3Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2
... HealthDay Reporter , MONDAY, Nov. 22 (HealthDay News) -- Children ... risk for experiencing a stroke compared with those whose parents, ... The finding stems from a survey of more than 13,000 ... when they were young children or adolescents. "I certainly ...
... mouse is helping researchers learn whether more muscle improves ... looking for ways to counteract the unhealthy effects of ... Medical College of Georgia Vascular Biology Center and co-director ... Obesity increases the risk for cardiovascular disease as well ...
... patients whose treatment is delayed not only become sicker than ... dollars more in care over the first several years of ... get people into care early because they will stay healthier ... M.D., M.P.H., an associate professor of medicine in the Division ...
... , MONDAY, Nov. 22 (HealthDay News) -- The pain of ... foot, elbow and lower back pain, a new study has ... osteoarthritis (OA) patients, aged 45 to 79, about pain in ... ankle or foot. Low back pain was significantly associated ...
... known for his groundbreaking work in biochemistry, received the ... joins an illustrious list of laureates which includes 15 ... his research related to artificial leaves and its creation ... research. This Medal has been awarded since 1921 to ...
... SATURDAY, Nov. 20 (HealthDay News) -- Kidney failure patients ... prescribed had significantly better heart function, overall health and ... finding stems from an analysis that compared the impact ... treatments per week, for three to four hours per ...
Cached Medicine News:Health News:Children of Divorce Face Twice the Lifetime Risk of Stroke: Study 2Health News:Children of Divorce Face Twice the Lifetime Risk of Stroke: Study 3Health News:Fat yet muscular mouse provides clues to improving cardiovascular health 2Health News:For HIV-positive patients, delayed treatment a costly decision 2Health News:Top Swedish scientist professor Bertil Andersson awarded prestigious Wilhelm Exner Medal in Vienna 2Health News:Top Swedish scientist professor Bertil Andersson awarded prestigious Wilhelm Exner Medal in Vienna 3Health News:Top Swedish scientist professor Bertil Andersson awarded prestigious Wilhelm Exner Medal in Vienna 4Health News:Top Swedish scientist professor Bertil Andersson awarded prestigious Wilhelm Exner Medal in Vienna 5Health News:Doubling Frequency of Dialysis May Help Kidney Failure Patients 2Health News:Doubling Frequency of Dialysis May Help Kidney Failure Patients 3
Inquire...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
Medicine Products: